Skip to main content
SpringerLink
Log in

Adding lapatinib to capecitabine not cost effective

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Le QA, Hay JW.Cost-effectiveness analysis of Lapatinib in HER-2-positive advanced breast cancer. Cancer 115: 489-498, No. 3, Feb 2009

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adding lapatinib to capecitabine not cost effective. Pharmacoecon. Outcomes News 574, 5 (2009). https://doi.org/10.2165/00151234-200905740-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905740-00013

Keywords

Search

Navigation